clinical trial · NCT05338775
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC·phase1·active not recruiting·n = 74
Relapsed/ Refractory Multiple MyelomaTalquetamabTeclistamabPD-1 Inhibitor
brief summary
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
started
May 25, 2022
primary completion
May 22, 2025
completion
May 3, 2027
last updated
May 8, 2026
official title
A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination With Checkpoint Inhibition for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol